A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

American Journal of Medicine

Volumn 113, Issue 4, 2002, Pages 294-299

  Villanueva, Alvaro ^a   Gotuzzo, Eduardo ^b   Arathoon, Eduardo G ^c   Noriega, L Miguel ^d   Kartsonis, Nicholas A ^e   Lupinacci, Robert J ^e   Smietana, Juanita M ^e   DiNubile, Mark J ^e   Sable, Carole A ^e  

^a Preventio   (Colombia)

^b HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^c Hospital General San Juan de Dios Guatemala   (Guatemala)

^d HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; CD4 ANTIGEN; FLUCONAZOLE; HEMOGLOBIN;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS MUCOSA; FEMALE; FEVER; FUNGUS ISOLATION; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; CHILE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; FLUCONAZOLE; GUATEMALA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PENNSYLVANIA; PEPTIDES; PEPTIDES, CYCLIC; PERU; TREATMENT OUTCOME;

EID: 0036701952     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01191-9     Document Type: Article

References (26)

1. Kaplan J.E., Hanson D., Dworkin M.S., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 30:(suppl 1):2000;S5-S14.
2. Centers for Disease Control and Prevention . Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 48:(RR-13):1999;1-27, 29-31.
3. Sangeorzan J.A., Bradley S.F., He X., et al. Epidemiology of oral candidiasis in HIV-infected patients colonization, infection, treatment, and emergence of fluconazole resistance . Am J Med. 97:1994;339-346.
4. Masia C.M., Guiterrez R.F., Ortiz-de-la-Tabla-Ducasse V., et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 19:2000;593-601.
5. Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 30:2000;662-678.
6. Ruhnke M., Eigler A., Tennagen I., et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 32:1994;2092-2098.
7. Newman S.L., Flanigan T.P., Fisher A., et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 19:1994;684-686.
8. Lacassin F., Damond F., Chochillon C., et al. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis pharmacological and mycological factors . Antimicrob Agents Chemother. 40:1996;1961-1963.
9. Landman D., Saurina G., Quale J.M. Failure of all antifungal therapy for infection due to Candida albicans a new AIDS-related problem . Clin Infect Dis. 26:1998;183-184.
10. Patel R. Antifungal agents. Part I amphotericin B preparations and flucytosine . Mayo Clin Proc. 73:1998;1205-1225.
11. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B recent progress and future directions . Clin Infect Dis. 22:(suppl 2):1996;S133-S144.
12. Andriole V.T. Current and future antifungal therapy new targets for antifungal agents . J Antimicrob Chemother. 44:1999;151-162.
13. Georgopapadakou N.H., Walsh T.J. Antifungal agents chemotherapeutic targets and immunologic strategies . Antimicrob Agents Chemother. 40:1996;279-291.
14. Marco F., Pfaller M.A., Messer S.A., Jones R.N. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis. 32:1998;33-37.
15. Barchiesi F., Schimizzi A.M., Fothergill A.W., et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis. 18:1999;302-304.
16. Douglas C.M., D'Ippolito J.A., Shei G.J., et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 41:1997;2471-2479.
17. Martinex-Suarez J.V., Rodriguez-Tudela J.L. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother. 40:1996;1277-1279.
18. Vazquez J.A., Lynch M., Boikov D., Sobel J.D. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother. 41:1997;1612-1614.
19. Pfaller M.A., Jones R.N., Doern G.V., et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents . Diagn Microbiol Infect Dis. 35:1999;19-25.
20. Pfaller M.A., Messer S.A., Gee S., et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol. 37:1999;870-872.
21. Graybill J.R., Najvar J.K., Luther M.F., Fothergill A.W. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother. 41:1997;1775-1777.
22. Graybill J.R., Bocanegra R., Luther M., et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother. 41:1997;1937-1939.
23. Walsh T.J., Gonzalez C.E., Piscitelli S., et al. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol. 38:2000;2369-2373.
24. Villanueva A., Arathoon E.G., Gotuzzo E., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of Candida esophagitis. Clin Infect Dis. 33:2001;1529-1535.
25. Arathoon E.G., Gotuzzo E., Noriega L.M., et al. A randomized, double-blind, multicenter study of caspofungin versus amphotericin in the treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 46:2002;451-457.
26. National Committee for Clinical Laboratory Standards . Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.